1. In Vivo

Pierre Fabre: Time to Reap R&D Rewards In-House

Recent Big Pharma deals validate Pierre Fabre's productive research, and underline mid-sized pharmas' importance as a product source. But the French group hasn't yet fully capitalized on its R&D.

By Melanie Senior

If Solvay SA completes its proposed acquisition of France's Fournier Pharma , announced in March 2005, Fournier's founding...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo